Rhythm Pharmaceuticals Inc
RYTM101.390USD
+1.180+1.18%
交易中 （美東）報價延遲15分鐘
6.48B總市值
虧損本益比TTM
關於 Rhythm Pharmaceuticals Inc 公司
Rhythm Pharmaceuticals, Inc. 是一家商業階段的生物製藥公司。該公司專注於推進其黑皮質素-4 受體 (MC4R) 激動劑，包括其主要資產 IMCIVREE，這是一種精準醫療，旨在治療由罕見的 MC4R 通路疾病引起的暴食症和嚴重肥胖症。IMCIVREE 已獲得美國食品藥品管理局 (FDA) 批准，用於治療因阿片黑皮質素原 (POMC)、前蛋白轉化酶枯草溶菌素/kexin 1 型 (PCSK1) 或瘦素受體 (LEPR) 缺乏而導致的單基因或綜合徵性肥胖的成人和 6 歲及以上的兒童患者的慢性體重管理，經 FDA 批准的測試確定，POMC、PCSK1 或 LEPR 基因中的變異被解釋爲致病、可能致病或意義不明 (VUS)；或 Bardet-Biedl 綜合徵 (BBS)。該公司正在 II 期和 III 期試驗中評估 setmelanotide 對治療因與 MC4R 通路相關的衆多基因之一變異而導致的肥胖症的效果。
Rhythm Pharmaceuticals Inc簡介
公司代碼RYTM
公司名稱Rhythm Pharmaceuticals Inc
上市日期Oct 05, 2017
CEO- -
員工數量283
證券類型Ordinary Share
年結日Oct 05
公司地址222 Berkeley Street
城市BOSTON
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02116
電話18572644280
網址https://rhythmtx.com/
公司代碼RYTM
上市日期Oct 05, 2017
CEO- -
Rhythm Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
201.82K
--
Mr. Hunter C. Smith
Mr. Hunter C. Smith
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
116.92K
--
Mr. Yann Mazabraud
Mr. Yann Mazabraud
Executive Vice President, Head of International
Executive Vice President, Head of International
37.66K
-6.73%
Mr. Joseph (Joe) Shulman
Mr. Joseph (Joe) Shulman
Chief Technical Officer
Chief Technical Officer
8.51K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
Independent Director
Independent Director
7.00K
+133.33%
Mr. Christophe R. Jean
Mr. Christophe R. Jean
Independent Director
Independent Director
7.00K
+133.33%
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Independent Director
Independent Director
7.00K
+133.33%
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Independent Director
Independent Director
7.00K
+133.33%
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Director
Independent Director
--
--
Dr. Alastair (Al) Garfield, Ph.D.
Dr. Alastair (Al) Garfield, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
201.82K
--
Mr. Hunter C. Smith
Mr. Hunter C. Smith
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
116.92K
--
Mr. Yann Mazabraud
Mr. Yann Mazabraud
Executive Vice President, Head of International
Executive Vice President, Head of International
37.66K
-6.73%
Mr. Joseph (Joe) Shulman
Mr. Joseph (Joe) Shulman
Chief Technical Officer
Chief Technical Officer
8.51K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
Independent Director
Independent Director
7.00K
+133.33%
Mr. Christophe R. Jean
Mr. Christophe R. Jean
Independent Director
Independent Director
7.00K
+133.33%
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2024
FY2023
FY2022
FY2021
暫無數據
地區USD
名稱
營收
佔比
United States
96.11M
73.86%
International
34.02M
26.14%
業務
地區
暫無數據
股東統計
更新時間: 8月15日 週五
更新時間: 8月15日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Baker Bros. Advisors LP
8.44%
RA Capital Management, LP
8.37%
PRIMECAP Management Company
7.34%
BlackRock Institutional Trust Company, N.A.
5.88%
The Vanguard Group, Inc.
5.39%
其他
64.58%
持股股東
持股股東
佔比
Baker Bros. Advisors LP
8.44%
RA Capital Management, LP
8.37%
PRIMECAP Management Company
7.34%
BlackRock Institutional Trust Company, N.A.
5.88%
The Vanguard Group, Inc.
5.39%
其他
64.58%
股東類型
持股股東
佔比
Investment Advisor
34.99%
Investment Advisor/Hedge Fund
28.82%
Hedge Fund
14.76%
Venture Capital
13.98%
Private Equity
4.02%
Research Firm
3.76%
Bank and Trust
0.73%
Individual Investor
0.67%
Pension Fund
0.35%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
449
67.58M
101.74%
-2.34M
2025Q2
451
66.54M
100.20%
-6.36M
2025Q1
464
66.24M
104.13%
-6.91M
2024Q4
438
66.17M
104.69%
-7.75M
2024Q3
414
68.98M
112.28%
-7.86M
2024Q2
402
70.62M
115.59%
-5.66M
2024Q1
385
68.75M
112.78%
-8.84M
2023Q4
369
67.33M
113.30%
-8.52M
2023Q3
350
68.72M
116.31%
-2.96M
2023Q2
327
67.69M
118.97%
+564.21K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Baker Bros. Advisors LP
5.60M
8.44%
--
--
Jun 30, 2025
RA Capital Management, LP
5.56M
8.37%
-523.05K
-8.60%
Jun 30, 2025
PRIMECAP Management Company
4.88M
7.34%
-909.28K
-15.71%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.91M
5.88%
-93.66K
-2.34%
Jun 30, 2025
The Vanguard Group, Inc.
3.58M
5.39%
+144.19K
+4.20%
Jun 30, 2025
New Enterprise Associates (NEA)
2.91M
4.38%
--
--
Jun 30, 2025
Perceptive Advisors LLC
2.42M
3.64%
-130.15K
-5.11%
Jun 30, 2025
Fidelity Management & Research Company LLC
1.91M
2.87%
+272.55K
+16.66%
Jun 30, 2025
State Street Global Advisors (US)
1.91M
2.87%
-63.13K
-3.20%
Jun 30, 2025
Westfield Capital Management Company, L.P.
1.63M
2.45%
+288.38K
+21.50%
Jun 30, 2025
查看更多
持股ETF
更新時間: 10月6日 週一
更新時間: 10月6日 週一
機構名稱
佔比
ALPS Medical Breakthroughs ETF
3.84%
Innovator IBD 50 Fund ETF
2.96%
Virtus LifeSci Biotech Products ETF
2.73%
Invesco Dorsey Wright Healthcare Momentum ETF
2.71%
Harbor Health Care ETF
2.15%
Harbor Human Capital Factor US Small Cap ETF
2.03%
iShares Health Innovation Active ETF
1.85%
SPDR S&P Biotech ETF
1.29%
Federated Hermes MDT Small Cap Core ETF
0.78%
Direxion Daily S&P Biotech Bull 3X Shares
0.78%
查看更多
ALPS Medical Breakthroughs ETF
佔比3.84%
Innovator IBD 50 Fund ETF
佔比2.96%
Virtus LifeSci Biotech Products ETF
佔比2.73%
Invesco Dorsey Wright Healthcare Momentum ETF
佔比2.71%
Harbor Health Care ETF
佔比2.15%
Harbor Human Capital Factor US Small Cap ETF
佔比2.03%
iShares Health Innovation Active ETF
佔比1.85%
SPDR S&P Biotech ETF
佔比1.29%
Federated Hermes MDT Small Cap Core ETF
佔比0.78%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.78%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
